A challenging economic environment is constricting biotech deal flow. But for well-capitalized Lantheus, these tough times ...

Lantheus Holdings, Inc. has a 52 week low of $58.46 and a 52 week high of $126.89. The stock has a market cap of $6.23 billion, a P/E ratio of 15.13 and a beta of 0.38. Want More Great Investing ...

Lantheus Holdings, Inc. has a 52 week low of $58.46 and a 52 week high of $126.89. The company’s 50-day moving average price is $93.32 and its two-hundred day moving average price is $95.80.

And in light of that, the trends we're seeing at Lantheus Holdings' (NASDAQ:LNTH) look very promising so lets take a look. The end of cancer? These 15 emerging AI stocks are developing tech that ...

Lantheus (LNTH) Holdings announced that it has completed its previously announced acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company. The acquisition was first ...

BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical ...

BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to ...

And in light of that, the trends we're seeing at Lantheus Holdings' (NASDAQ:LNTH) look very promising so lets take a look. The end of cancer? These 15 emerging AI stocks are developing tech that will ...

Short interest in Lantheus Holdings Inc (NASDAQ:LNTH) decreased during the last reporting period, falling from 6.46M to 6.42M. This put 12.34% of the company's publicly available shares short.

BEDFORD, Mass. - Lantheus Holdings, Inc. (NASDAQ: LNTH), a leader in the radiopharmaceutical industry, announced today the completion of its acquisition of Evergreen Theragnostics, Inc., a ...